CD274 and non-small cell lung carcinoma: Given these pleiotropic immune activating effects, the combination of mocetinostat and the PD-L1 blocking mAb durvalumab was tested in NSCLC patients (pts) with checkpoint inhibitor therapy (CIT) naïve disease or had progressive disease after prior CIT.